Theravance Biopharma Inc (TBPH) — Working Capital to Net Assets Ratio
Theravance Biopharma Inc (TBPH) has a Working Capital to Net Assets ratio of 128.1% as of December 2025. Working capital of $380.16 Million (current assets of $418.46 Million minus current liabilities of $38.30 Million) is measured against net assets of $296.72 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Theravance Biopharma Inc balance sheet independence to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Theravance Biopharma Inc Working Capital to Net Assets (2011–2025)
This chart shows how Theravance Biopharma Inc's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of December 2025, the ratio stands at 128.1%, reflecting working capital of $380.16 Million against net assets of $296.72 Million USD. Check tangible equity quality of Theravance Biopharma Inc to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Theravance Biopharma Inc (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Theravance Biopharma Inc from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market cap of Theravance Biopharma Inc.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 128.1% | $380.16 Million | $296.72 Million | $418.46 Million | $38.30 Million | ▲ +54.6 pp |
| 2024 | 73.5% | $128.98 Million | $175.54 Million | $161.07 Million | $32.09 Million | ▲ +22.4 pp |
| 2023 | 51.1% | $108.77 Million | $213.00 Million | $133.54 Million | $24.77 Million | ▼ -22.4 pp |
| 2022 | 73.5% | $324.75 Million | $441.80 Million | $353.46 Million | $28.71 Million | ▲ +130.0 pp |
| 2021 | -56.5% | $191.28 Million | $-338.57 Million | $249.87 Million | $58.59 Million | ▲ +32.3 pp |
| 2020 | -88.8% | $269.77 Million | $-303.75 Million | $393.34 Million | $123.57 Million | ▲ +12.5 pp |
| 2019 | -101.3% | $226.78 Million | $-223.84 Million | $338.49 Million | $111.70 Million | ▲ +740.5 pp |
| 2018 | -841.8% | $434.27 Million | $-51.59 Million | $532.82 Million | $98.55 Million | ▼ -1116.3 pp |
| 2017 | 274.5% | $316.20 Million | $115.18 Million | $378.75 Million | $62.55 Million | ▲ +137.7 pp |
| 2016 | 136.8% | $479.24 Million | $350.23 Million | $528.50 Million | $49.27 Million | ▲ +59.5 pp |
| 2015 | 77.3% | $188.00 Million | $243.06 Million | $237.47 Million | $49.47 Million | ▼ -21.2 pp |
| 2014 | 98.5% | $285.51 Million | $289.79 Million | $326.77 Million | $41.26 Million | ▼ -35.0 pp |
| 2013 | 133.5% | $-22.75 Million | $-17.04 Million | $14.11 Million | $36.85 Million | ▼ -558.7 pp |
| 2012 | 692.2% | $-11.84 Million | $-1.71 Million | $10.84 Million | $22.67 Million | ▲ +668.4 pp |
| 2011 | 23.9% | $-33.56 Million | $-140.72 Million | $2.32 Million | $35.88 Million | — |